Back to today’s briefing

Story perspectives

India's Anti-Obesity Drug Market Soars Amid Concerns

11/5/2025

26 4

Summary

Story summary

India's anti-obesity drug market grew from $16 million in 2021 to $100 million in 2025, driven by GLP-1 medications such as semaglutide and tirzepatide.
Doctors warn that these drugs are not substitutes for lifestyle changes.
The drugs can cause muscle loss if misused.
Concerns about misuse and influx of generic versions loom as the market expands.
Obesity is now recognized as a chronic disease, prompting a shift in society's perception.

1 of 1

Story summary

India's anti-obesity drug market grew from $16 million in 2021 to $100 million in 2025, driven by GLP-1 medications such as semaglutide and tirzepatide.
Doctors warn that these drugs are not substitutes for lifestyle changes.
The drugs can cause muscle loss if misused.
Concerns about misuse and influx of generic versions loom as the market expands.
Obesity is now recognized as a chronic disease, prompting a shift in society's perception.